Advertisement


Smita Bhatia, MD, MPH: Some Clonal Mutations May Predict Therapy-Related Myeloid Neoplasms

2022 ASH Annual Meeting and Exposition

Advertisement

Smita Bhatia, MD, MPH, of the Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, discusses study findings that showed key somatic mutations in the peripheral blood stem cell product increases the risk of developing therapy-related myeloid neoplasms (Abstract 119).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Therapy related leukemia is a lethal complication of autologous transplantation for Hodgkin lymphoma and non-Hodgkin lymphoma. Now, there are some very well known clinical factors that increase the risk. These include older age at transplantation, pre-transplant exposures to alkylating agents and radiation, and then exposure to total body radiation, and a lower dose of CD34 positive cells that are infused. More recently, there has been increasing attention to what's called clonal hematopoiesis. These are somatic mutations that are present in the peripheral blood, which are in healthy people known to increase the risk of subsequent leukemia. And these have also been studied recently in cancer patients. But there are some gaps in knowledge and these are, what are the factors associated with clonal hematopoiesis? Whether it is just older age, or any treatments increase the risk? And then are there specific mutations that increase the risk of therapy related leukemia? So we addressed this gap in about 1,328 patients with lymphoma, where we had cryopreserved peripheral blood stem cells. We looked at specific mutations and found that they were present in 33% of our survivors. And one third had multiple mutations, two thirds had a single mutation. And we found that there was a clear association between multiple mutations and therapy related leukemia, not with single mutations. So that was a novel finding for us. Going forward beyond that, we also found that Hodgkin lymphoma patients were at a higher risk of therapy related leukemia, as were males. And what we did was then we dug in deeper and found in males PPM1D increased the risk of therapy related leukemia. While in females, there was no association within these clonal hematopoiesis and therapy related leukemia. When we look at Hodgkin lymphoma and non-Hodgkin lymphoma patients, it's primarily TP53 mutations which increase the risk. Coming back to specific mutations, we find that TP53, any TP53 mutations, confer the highest risk. This is followed by any PPM1D mutations, while presence of DNMT3A mutations alone, without any PPM1D or TP53 mutations, don't confer any risk at all. Presence of single or multiple mutations are associated with non relapse mortality, not with relapse related mortality. So in conclusion, what we find is that older age and exposure to therapy related factors such as alkylating agents increase the risk of clonal hematopoiesis. And then amongst the patients who have clonal hematopoiesis, it's the male sex, Hodgkin lymphoma and presence of multiple mutations that increase the risk. And also the fact that PPM1D and TP53 are the major driving forces here. Where do we want to go next? We need to see how these key mutations interact with hematopoietic stressors and use this information to further our understanding of the pathogenesis of therapy related leukemia, and also to develop predictors that help us understand who's at risk for therapy related leukemia.

Related Videos

Leukemia

Andrew Matthews, MD, on AML: Real-World Effectiveness of 7 + 3 Intensive Chemotherapy vs Venetoclax and a Hypomethylating Agent

Andrew Matthews, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses findings from a large, multicenter study that showed superior outcomes with 7 + 3 chemotherapy (cytarabine continuously for 7 days, along with short infusions of an anthracycline on each of the first 3 days) vs venetoclax in patients with acute myeloid leukemia (AML). In this real-world data set, the 7 + 3 cohort outperformed historical benchmarks in overall survival and early mortality, perhaps reflecting improved later lines of therapy and patient selection. Prospective studies (such as NCT04801797) must confirm the superiority of intensive chemotherapy (Abstract 426).

 

Leukemia

Jorge E. Cortes, MD, on CML: Efficacy and Safety of Vodobatinib

Jorge E. Cortes, MD, of Georgia Cancer Center at Augusta University, discusses new findings on vodobatinib, which was administered to patients with chronic-phase Philadelphia chromosome–positive chronic myeloid leukemia (CML) and appeared to be efficacious and safe in people who had received therapy with two or three prior tyrosine kinase inhibitors (TKIs). Vodobatinib remains a potential option for these highly refractory patients. A phase II study (NCT02629692) of vodobatinib is ongoing in CML patients whose disease has failed to respond to three or more TKIs, including ponatinib (Abstract 84).

Multiple Myeloma

Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).

Lymphoma

Alex F. Herrera, MD, on Previously Untreated DLBCL: Circulation Tumor DNA and Risk Profiling

Alex F. Herrera, MD, of the City of Hope National Medical Center, discusses results from the POLARIX study, which showed that circulating tumor DNA (ctDNA) analysis has prognostic value for patients with previously untreated diffuse large B-cell lymphoma. Patients who did not achieve 2.5 or greater log-fold change and/or did not have ctDNA clearance following one cycle of polatuzumab vedotin along with rituximab, cyclophosphamide, doxorubicin, and prednisone had inferior outcomes than those who did. Early changes in ctDNA levels may be of use in risk-adapted trial designs to identify patients in need of alternative treatment. (Abstract 542).

Leukemia

Anand P. Jillella, MD, on Acute Promyelocytic Leukemia: A Simplified Patient Care Strategy to Decrease Early Deaths

Anand P. Jillella, MD, of Georgia Cancer Center at Augusta University, discusses results from the ECOG-ACRIN EA9131 Trial, which showed that using a simplified treatment algorithm and management recommendations made by a group of specialists, resulted in a dramatic improvement in 1-year survival of patients with acute promyelocytic leukemia (Abstract 421).

Advertisement

Advertisement




Advertisement